A Patient-Centered Model of Congenital Thrombotic Thrombocytopenic Purpura Symptoms and Effects
Researchers interviewed clinicians and patients to develop a conceptual model of congenital thrombotic thrombocytopenic purpura.
Thrombotic Thrombocytopenic Purpura
A New Standard of Care for Immune-Mediated Thrombotic Thrombocytopenic Purpura?
Combining caplacizumab with therapeutic plasma exchange could decrease hospital stays and treatment costs in the long term.
Underlying Connective Tissue Disorders in TTP Result in Longer, More Expensive Hospitalizations
A higher proportion of black patients and female patients with thrombotic thrombocytopenic purpura had coexisting connective tissue disorders.
Using the PLASMIC Score to Risk Stratify Patients With Immune Thrombotic Thrombocytopenic Purpura
Utilizing a PLASMIC score-based algorithm may reduce treatment costs by reducing overutilization of therapeutic plasma exchange and expert consultations.
From Fatal to Curable: Immune-Mediated Thrombotic Thrombocytopenic Purpura
Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
Relapse Predictors in Immune Thrombotic Thrombocytopenic Purpura After Rituximab Treatment
Rituximab treatment conferred short-term benefit against subsequent relapse, though this benefit decreased over time.
Low Antigen Level May Be an Indication for Splenectomy in Relapsing Thrombotic Thrombocytopenic Purpura
Researchers described 2 patients with refractory thrombotic thrombocytopenic purpura who regained normal ADAMTS13 levels after splenectomy.
Equivalence Between Rituximab Originator and Biosimilar in Immune Thrombocytopenic Purpura
Platelet counts, ADAMTS13 recovery, and infective complications were not significantly different between the 2 treatment groups.
Managing Pediatric Systemic Lupus Erythematosus in Thrombotic Thrombocytopenic Purpura
Researchers recommended performing lactate dehydrogenase level and blood smear testing in patients with renal and neurological symptoms.
Caplacizumab Associated With Improved Outcomes in Acquired Thrombotic Thrombocytopenic Purpura
Patients receiving caplacizumab experienced faster normalization of platelet count and fewer adverse events compared with patients on placebo.
Next post in Thrombotic Disorders
